Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings Inc    ZBH

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Zimmer Holdings, Inc. : Zimmer Receives FDA Warning on Certain Hip Implants

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2012 | 12:40am CEST

--Zimmer says FDA inspection of Puerto Rico plant turned up concerns about manufacturing of certain implants

--FDA in letter noted manufacturing, testing issues related to Trilogy Acetabuar System products, company says

--Zimmer says it is notifying customers of manufacturing issue, but hasn't withdrawn any products

(Adds context on metallic spikes in fourth paragraph and a no comment from Zimmer in seventh paragraph.)

 
   By Kristin Jones 
 

Zimmer Holdings Inc. (ZMH) said a U.S. Food and Drug Administration inspection of its plant in Puerto Rico turned up concerns about the manufacturing of certain hip implants.

The orthopedic maker's Zimmer Inc. subsidiary received a warning letter from the FDA dated Sept. 19, the company said in a regulatory filing Monday. In the letter, the FDA noted manufacturing and testing issues related to the company's Trilogy Acetabular System products, which are implanted in hip-replacement surgery.

Specifically, the U.S. drug regulator noted that Zimmer hadn't implemented a testing mechanism to show that its products met design specifications. The company also hadn't validated the effect of certain manufacturing operations on Trilogy products that incorporate metallic spikes.

Spikes are used to connect the hip replacement cup to a patient's bone when cement and screws are deemed insufficient.

The FDA requires that drug and medical-device makers undertake steps to ensure the quality of the design and manufacture of its products, known as process validation.

Zimmer said it is notifying customers of the manufacturing issue, but that it hasn't withdrawn any products. The company also said it previously suspended release of the spiked products, pending validation of the processes cited in the letter, and expects to complete validation in the next few weeks.

A Zimmer spokesman declined to comment further.

Shares gained 11 cents to $67.98 in after-hours trading. Through Monday's close, the stock was up 27% so far this year.

--Joseph Walker contributed to this article.

Write to Kristin Jones at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIMMER BIOMET HOLDINGS INC
05/23 ZIMMER BIOMET : Bone Growth Stimulating Equipment Market 2017 - DJO, IGEA, Elizu..
05/18 ZIMMER BIOMET : Named Top Workplace on Forbes' "America's Best Large Employers o..
05/18 ZIMMER BIOMET : licenses Intellectual Property from Bonutti Research Inc.
05/17 ZIMMER BIOMET HOLDINGS, INC. (NYSE : ZBH) Files An 8-K Submission of Matters to ..
05/17 ZIMMER BIOMET HOLDINGS, INC. : Submission of Matters to a Vote of Security Holde..
05/09 ZIMMER BIOMET : May 9, 2017 Zimmer Biomet Named Top Workplace on Forbes' "Americ..
05/09 ZIMMER BIOMET : Management's Discussion and Analysis of Financial Condition and ..
05/09 INSIDER TRADING ACTIVITY ZIMMER BIOM : ZBH) – VP Sold 6,200 shares of Stoc..
05/08 ZIMMER BIOMET : May 8, 2017 Zimmer Biomet Holdings to Present at the Bank of Ame..
04/27 ZIMMER BIOMET HOLDINGS, INC. (NYSE : ZBH) Files An 8-K Results of Operations and..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
05/23DJFirms Persuade SEC on Profit Metric -- WSJ
05/22DJCompanies Are Winning the Battle Over Adjusted Earnings
05/16 Earnings drag on European shares, though Vodafone lifts telcos
05/09 French outbound M&A driven to decade high by big deals
05/06DJProfits Jump, Spending Lags -- WSJ
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
04:12a Tracking Larry Robbins's Glenview Capital Management Portfolio - Q1 2017 Upda..
05/16 Premarket analyst action - healthcare
04/27 Zimmer Biomet Holdings' (ZBH) CEO David Dvorak on Q1 2017 Results - Earnings ..
04/27 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
04/27 PREMARKET LOSERS AS OF 9 : 05 am
Advertisement
Financials ($)
Sales 2017 7 866 M
EBIT 2017 2 490 M
Net income 2017 1 207 M
Debt 2017 9 294 M
Yield 2017 0,79%
P/E ratio 2017 22,44
P/E ratio 2018 17,46
EV / Sales 2017 4,23x
EV / Sales 2018 3,96x
Capitalization 24 016 M
More Financials
Chart ZIMMER BIOMET HOLDINGS INC
Duration : Period :
Zimmer Biomet Holdings Inc Technical Analysis Chart | ZBH | US98956P1021 | 4-Traders
Full-screen chart
Technical analysis trends ZIMMER BIOMET HOL...
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 131 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David C. Dvorak President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Adrian Furey Senior VP-Global Operations & Logistics
Daniel P. Florin Chief Financial Officer & Senior Vice President
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS..15.41%23 752
MEDTRONIC PLC18.78%114 973
BAXTER INTERNATIONAL I..31.57%31 343
C R BARD INC37.29%22 251
HOYA CORPORATION11.22%19 129
TERUMO CORP3.35%14 795
More Results